A laboratory phenotype/genotype correlation of 1167 French patients from 670 families with von willebrand disease: A new epidemiologic picture

Medicine (United States)

Volumn 95, Issue 11, 2016, Pages

  Veyradier, Agnès ^a   Boisseau, Pierre ^b   Fressinaud, Edith ^c   Caron, Claudine ^d   Ternisien, Catherine ^b   Giraud, Mathilde ^b   Zawadzki, Christophe ^d   Trossaert, Marc ^b   Itzhar Baïkian, Nathalie ^a   Dreyfus, Marie ^e   D'Oiron, Roseline ^e   Borel Derlon, Annie ^f   Susen, Sophie ^d   Bezieau, Stéphane ^b   Denis, Cécile V ^c   Goudemand, Jenny ^d  

^a HÔPITAL LARIBOISIÈRE   (France)

^b HÔTEL DIEU   (France)

^c Dept Environ Med Natl Inst Publ HIth   (Norway)

^d LILLE UNIVERSITY HOSPITAL   (France)

^e BICÊTRE HOSPITAL   (France)

^f CAEN UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 2; GLYCOPROTEIN IB; VON WILLEBRAND FACTOR;

ADOLESCENT; ADULT; ARTICLE; CHILD; DIAGNOSTIC ACCURACY; FEMALE; FRENCHMAN; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC COUNSELING; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; VON WILLEBRAND DISEASE; AGED; FRANCE; GENETICS; GENOTYPE; MIDDLE AGED; MUTATION; PHENOTYPE; PRESCHOOL CHILD; VERY ELDERLY; VON WILLEBRAND DISEASES; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; FEMALE; FRANCE; GENOTYPE; HUMANS; INFANT; MALE; MIDDLE AGED; MUTATION; PHENOTYPE; VON WILLEBRAND DISEASES; YOUNG ADULT;

EID: 84962023354     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000003038     Document Type: Article

References (57)

1. Sadler JE. Von Willebrand factor in its native environment. Blood. 2013;121:2583-2584.
2. Zhou YF, Eng ET, Zhu J, et al. Sequence and structure relationships within von Willebrand factor. Blood. 2012;120:449-458.
3. Lenting PJ, Christophe OD, Denis CV. Von Willebrand factor biosynthesis, secretion, and clearance: connecting the far ends. Blood. 2015;125:2019-2028.
4. Goodeve AC. The genetic basis of von Willebrand disease. Blood Rev. 2010;24:123-134.
5. James PD, Goodeve AC. Von Willebrand disease. Genet Med. 2011;13:365-376.
6. Sadler JE. New concepts in von Willebrand disease. Annu Rev Med. 2005;56:173-191.
7. Federici AB, Budde U, Castaman G, et al. Current diagnostic and therapeutic approaches to patients with acquired von Willebrand syndrome: a 2013 update. Semin Thromb Haemost. 2013;39: 191-201.
8. Laffan MA, Lester W, O'Donnell JS, et al. The diagnosis and management of von Willebrand disease: a United Kingdom Haemophilia Centre Doctors' Organisation guideline approved by the British Committee for Standards in Haematology. Br J Haematol. 2014;167:453-465.
9. Sadler JE, Budde U, Eikenboom JC, et al. Working Party on von Willebrand Disease Classification. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost. 2006;4:2103-2114.
10. Sadler JE. Low von Willebrand factor: sometimes a risk factor and sometimes a disease. Hematology Am Soc Hematol Educ Program. 2009:106-112.
11. Goodeve A, Eikenboom J, Castaman G, et al. Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European Study, Molecular and Clinical Markers for the Diagnosis and Management of type 1 von Willebrand disease (MCMDM-1VWD). Blood. 2007;109: 112-121.
12. James PD, Lillicrap D, Mannucci PM. Alloantibodies in von Willebrand disease. Blood. 2013;122:636-640.
13. Tosetto A, Castaman G. How I treat type 2 variant forms of von Willebrand disease. Blood. 2015;125:907-914.
14. Jacobi PM, Gill GC, Flood VH, et al. Intersection of mechanisms of type 2A VWD through defects in VWF multimerization, secretion, ADAMTS13 susceptibility, and regulated storage. Blood. 2012;119:4543-4553.
15. Baronciani L, Federici AB, Castaman G, et al. Prevalence of type 2B "Malmö/New York" von Willebrand disease in Italy: the role of von Willebrand factor gene conversion. J Thromb Haemost. 2008;6:887-890.
16. Gezsi A, Budde U, Deak I, et al. Accelerated clearance alone explains ultra-large multimers in von Willebrand disease Vicenza. J Thromb Haemost. 2010;8:1273-1280.
17. Ng C, Motto DG, Di Paola J. Diagnostic approach to von Willebrand disease. Blood. 2015;125:2029-2037.
18. Lillicrap D. Von Willebrand disease: advances in pathogenic understanding, diagnosis, and therapy. Hematology Am Soc Hematol Educ Program. 2013;2013:254-260.
19. Eikenboom J, Federici AB, Dirven RJ, et al. MCMDM-1VWD Study Group. VWF propeptide and ratios between VWF, VWF propeptide, and the FVIII in the characterization of type 1 von Willebrand disease. Blood. 2013;121:2336-2339.
20. Flood VH, Lederman CA, Wren JS, et al. Absent collagen binding in a VWF A3 domain mutant: utility of the VWF:CB in diagnosis of VWD. J Thromb Haemost. 2010;8:1431-1433.
21. De Brasi C, El-Maari O, Perry DJ, et al. Genetic testing in bleeding disorders. Haemophilia. 2014;20(Suppl. 4):54-58.
22. Keeney S, Bowen D, Cumming A, et al., UK Haemophilia Centre Doctors' Organisation (UKHCDO). The molecular analysis of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors' Organisation Haemophilia Genetics Laboratory Network. Haemophilia. 2008;14:1099-1111.
23. Othman M, Emsley J. Platelet-type von Willebrand disease: toward an improved understanding of the "sticky situation". Semin Thromb Hemost. 2014;40:146-150.
24. Castaman G, Lethagen S, Federici AB, et al. Response to desmopressin is influenced by the genotype and the phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1 VWD. Blood. 2008;111:3531-3539.
25. Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand's disease. Blood. 1987;69: 454-459.
26. Werner EJ, Broxson EH, Tucker EL, et al. Prevalence of von Willebrand disease in children: a multiethnic study. J Pediatr. 1993;123:893-898.
27. Fressinaud E, Veyradier A, Truchaud F, et al. Screening for von Willebrand disease with a new analyzer using high shear stress: a study of 60 cases. Blood. 1998;91:1325-1331.
28. Budde U, Pieconka A, Will K, et al. Laboratory testing for von Willebrand disease: contribution of multimer analysis to diagnosis and classification. Semin Thromb Hemost. 2006;32:514-521.
29. Caron C, Hilbert L, Vanhoorelbeke K, et al. Measurement of von Willebrand factor binding to a recombinant fragment of glycoprotein Ibalpha in an enzyme-linked immunosorbent assay-based method: performance in patients with type 2B von Willebrand disease. Br J Haematol. 2006;133:655-663.
30. Favaloro EJ. Collagen binding assay for von Willebrand factor (VWF: CBA): detection of von Willebrand disease (VWD) and discrimination of VWD subtypes, depends on collagen source. Thromb Haemost. 2000;83:127-135.
31. Caron C, Mazurier C, Goudemand J. Large experience with a factor VIII binding assay of plasma von Willebrand factor using commercial reagents. Br J Haematol. 2002;117:716-718.
32. Haberichter SL, Castaman G, Budde U, et al. Identification of type 1 von Willebrand disease with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD). Blood. 2008;111:4979-4985.
33. Federici AB, Bucciarelli P, Castaman G, et al. The bleeding score predicts clinical outcomes and replacement therapy in adults with von Willebrand disease. Blood. 2014;123:4037-4044.
34. James PD, Lillicrap D. The diagnosis and management of von Willebrand disease in Canada. Semin Thromb Haemost. 2011;37:522-527.
35. Flood VH, Gill JC, Bellissimo DB, et al. Von Willebrand disease in the United States: a perspective from Wisconsin. Semin Thromb Haemost. 2011;37:528-534.
36. Yadegari H, Driesen J, Pavlova A, et al. Mutation distribution in the von Willebrand factor gene related to the different von Willebrand disease (VWD) types in a cohort of VWD patients. Thromb Haemost. 2012;108:662-671.
37. Sanders YV, Groeneveld D, Meijer K, et al. WIN study group. Von Willebrand factor propeptide and the phenotypic classification of von Willebrand disease. Blood. 2015;125:3006-3013.
38. Battle J, Perez-Rodriguez A, Corrales I, et al. Molecular and clinical profile of von Willebrand disease in Spain (PCM-EVW-ES): proposal for a new diagnostic paradigm. Thromb Haemost. 2015;114 (6.)Epub ahead of print.
39. Bowman M, Tuttle A, Notley C, et al. Association of Hemophilia Clinic Directors of Canada. The genetics of Canadian type 3 von Willebrand disease: further evidence for co-dominant of mutant alleles. J Thromb Haemost. 2013;11:512-520.
40. Sutherland MS, Keeney S, Bolton-Maggs PH, et al. The mutation spectrum associated with type 3 von Willebrand disease in a cohort of patients from the north west of England. Haemophilia. 2009;15:1048-1057.
41. Solimando M, Baronciani L, La Marca S, et al. Molecular characterization, recombinant protein expression, and mRNA analysis of type 3 von Willebrand disease: studies of an Italian cohort of 10 patients. Am J Hematol. 2012;87:870-874.
42. Shahbazi S, Mahdian R, Ala FA, et al. Molecular characterization of Iranian patients with type 3 von Willebrand disease. Haemophilia. 2009;15:1058-1064.
43. Kasatkar P, Shetty S, Ghosh K. Genetic heterogeneity in a large cohort of Indian type 3 von Willebrand disease patients. PLoS One. 2014;9:e92575.
44. James PD, Notley C, Hegadom C, et al. The mutational spectrum of type 1 von Willebrand disease: results from a Canadian cohort study Blood. 2007;109:145-154.
45. Eikenboom J, Hilbert L, Ribba AS, et al. Expression of 14 von Willebrand factor mutations identified in patients with type 1 von Willebrand disease from the MCMDM-1VWD study. J Thromb Haemost. 2009;7:1304-1312.
46. Peake I, Goodeve A. Type 1 von Willebrand disease. J Thromb Haemost. 2007;5(Suppl. 1):7-11.
47. Sutherland MS, Cumming AM, Bowman M, et al. A novel deletion mutation is recurrent in von Willebrand disease types 1 and 3. Blood. 2009;114:1091-1098.
48. Goodeve AC. VWF sequence variants: a data goldmine. Blood. 2013;122:471-473.
49. Ahmad F, Jan R, Kannan M, et al. Characterisation of mutations and molecular studies of type 2 von Willebrand disease. Thromb Haemost. 2013;109:39-46.
50. Meyer D, Fressinaud E, Gaucher C, et al. Gene defects in 150 unrelated French cases with type 2 von Willebrand disease: from the patient to the gene. INSERM network on molecular abnormalities in von Willebrand disease. Thromb Haemost. 1997;78:451-456.
51. Meyer D, Fressinaud E, Mazurier C. Clinical laboratory and molecular markers of type 2 von Willebrand disease. In: Federici AB, Lee CA, Berntop E, Lillicrap D, Montgomery RR, eds. Vo n Willebrand disease: basic and clinical aspects. Wiley-Blackwell; 2011:137-147.
52. Schneppenheim R, Michiels JJ, Obser T, et al. A cluster of mutations in the D3 domain of von Willebrand factor correlates with a distinct subgroup of von Willebrand disease: type 2A/IIE. Blood. 2010;115:4894-4901.
53. Nurden P, Gobbi G, Nurden A, et al. Abnormal VWF modifies megakaryocytopoiesis: studies of platelets and megakaryocyte cultures from patients with von Willebrand disease type 2B. Blood. 2010;115:2649-2656.
54. Castaman G, Federici AB, Tosetto A, et al. Different bleeding risk in type 2A and 2M von Willebrand disease: a 2-year prospective study in 107 patients. J Thromb Haemost. 2012;10:632-638.
55. Mazurier C, Goudemand J, Hilbert L, et al. Type 2N von Willebrand disease: clinical manifestations, pathophysiology, laboratory diagnosis and molecular biology. Best Pract Res Clin Haematol. 2001;14:337-347.
56. Hampshire DJ, Goodeve AC. The molecular basis of von Willebrand disease: the under investigated, the unexpected and the overlooked. Haematologica. 2011;96:798-800.
57. Flood VH. New insights into genotype and phenotype of VWD. Hematology Am Soc Hematol Educ Program. 2014;2014:531-535.